Skip to main content
TipRanks
Go Ultimate75% OFF

VistaGen Therapeutics (VTGN) Stock Price & Analysis

1,154 Followers

VTGN Stock Chart & Stats

$0.16-$0.02(-12.37%)
At close: 4:00 PM EST
$0.2$0.3Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$0.16 - $0.19
52-Week Range
$0.16 - $5.14
Previous Close
$0.19
Volume
N/A
Average Volume (3M)
813.64K
Market Cap
$7.56M
Enterprise Value
-$5.75M
Total Cash (Recent Filing)
$20.03M
Total Debt (Recent Filing)
$610.00K
Price to Earnings (P/E)
―
Beta
0.83
Next Earnings
Feb 11, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Regulatory Path

Constructive FDA feedback gives VistaGen a clearer path for refining fasedienol’s Phase 3 program, reducing uncertainty around endpoint selection and study design. This regulatory alignment can improve development efficiency and strengthen the candidate’s prospects for advancing toward potential approval.

Clinical Tolerability

Long-term extension data showing favorable tolerability across 322 participants supports continued use of fasedienol and may help its clinical positioning. Low adverse-event discontinuation and no serious treatment-attributed events are durable positives for development and adoption potential.

Low Leverage And Gross Margin

Very low debt reduces immediate balance-sheet pressure, while the roughly 78% gross margin indicates the company can generate substantial gross profit on existing revenue. Together, these features leave operating expenses, rather than financing costs or delivery economics, as the primary improvement opportunity.

Bears Say

Sustained Cash Burn

Persistent operating and free-cash-flow losses mean VistaGen is consuming substantial cash to sustain its activities rather than funding them internally. Continued reliance on external financing can constrain strategic flexibility and create recurring funding or dilution pressure over the next several quarters.

Limited Commercial Scale

The company has limited commercial scale relative to its operating cost base, with modest and declining revenue alongside very large operating and net losses. This gap indicates that substantial execution and development progress is still required before the business can approach sustainable profitability.

Shrinking Equity Base

The sharp reduction in equity signals that accumulated losses and/or dilution have materially weakened the capital base. A smaller equity cushion can increase shareholder sensitivity to future financing needs and reduce financial resilience while VistaGen continues funding clinical development.

VistaGen Therapeutics News

VTGN FAQ

What was VistaGen Therapeutics’s price range in the past 12 months?
VistaGen Therapeutics lowest stock price was $0.16 and its highest was $5.14 in the past 12 months.
What is VistaGen Therapeutics’s market cap?
VistaGen Therapeutics’s market cap is $7.56M.
When is VistaGen Therapeutics’s upcoming earnings report date?
VistaGen Therapeutics’s next earnings report is estimated for Feb 11, 2027 (not yet confirmed), which is in 81 days.
How were VistaGen Therapeutics’s earnings last quarter?
VistaGen Therapeutics released its earnings results on Nov 13, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.375 by $0.135.
Is VistaGen Therapeutics overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does VistaGen Therapeutics pay dividends?
VistaGen Therapeutics does not currently pay dividends.
What is VistaGen Therapeutics’s EPS estimate?
VistaGen Therapeutics’s EPS estimate is -0.32.
How many shares outstanding does VistaGen Therapeutics have?
VistaGen Therapeutics has 46,186,050 shares outstanding.
What happened to VistaGen Therapeutics’s price movement after its last earnings report?
VistaGen Therapeutics reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.375. Following the earnings report the stock price went up 2.222%.
Which hedge fund is a major shareholder of VistaGen Therapeutics?
Hedge funds hold VistaGen Therapeutics shares: the largest hedge-fund position in VistaGen Therapeutics is 72,328,798 shares, and hedge funds decreased their holdings by 3.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology